Drug Profile
Research programme: ubiquitination protein degradation therapeutics - BeyondSpring Pharmaceuticals
Alternative Names: BPI-001Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator BeyondSpring Pharmaceuticals
- Class Antineoplastics; Ligases
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Aug 2018 Preclinical trials in Cancer in USA (unspecified route) (BeyondSpring Pharmaceuticals pipeline, August 2018)
- 21 Jun 2018 BeyondSpring Pharmaceuticals plans clinical development of BPI 001 in 2019